Blinatumomab in Relapsed/Refractory Burkitt Lymphoma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Relapsed/refractory Burkitt lymphoma (r/r BL) has a poor prognosis with limited effective treatment options.
• Blinatumomab, a bispecific monoclonal antibody, is a potential novel therapy for r/r BL.
• Limited data exist on blinatumomab's efficacy and safety in r/r BL.

Purpose of the Study:

• To investigate the safety and efficacy of blinatumomab in patients with r/r BL.
• To assess adverse events, including cytokine release syndrome and neurotoxicity.
• To evaluate progression-free survival, overall survival, and overall response rate.

Main Methods:

• Multi-center, retrospective case series.
• Nine patients with r/r BL treated with blinatumomab.
• Safety assessment of adverse effects (AEs), infections, cytokine release syndrome (CRS), and neurotoxicity.
• Efficacy analysis of progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).

Main Results:

• No adverse events greater than grade 2 were observed; AEs were manageable and reversible.
• Overall response rate (ORR) included complete remission (3/9) and partial remission (2/9).
• Median PFS was 2 months and median OS was 6 months.
• Blinatumomab served as a successful bridge to stem cell transplantation in 3/9 patients.

Conclusions:

• Blinatumomab demonstrates safety and evident activity in some patients with r/r BL.
• Response to blinatumomab varied, with some patients experiencing long-term survival.
• Prospective investigation of blinatumomab in r/r BL is warranted.